Vaccine Type-, Age- and Past Infection-Dependence of the Humoral Response to SARS-CoV-2 Spike S Protein

Romero-Pinedo, Salvador; Quesada, Marina; Horndler, Lydia; Álvarez-Fernández, Stela; Olmo, Alberto; Abia, David; Alarcón, Balbino; Delgado, Pilar

doi:10.3389/fimmu.2022.809285

Cited by 8 publications

(11 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The immunogenicity of the different vaccines upon completion of primary vaccination was compared in the population. This analysis revealed that both seroconversion rates and the levels of IgG reactive to Spike and S1 RBD were higher on those participants vaccinated with BNT16b2, followed by ChAdOx1 and CoronaVac, in agreement with other studies (Barin et al 2022;Romero-Pinedo et al 2022). Quite remarkably, the seroconversion rates for Spike binding antibodies determined in our study (Fig.…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Populational analysis of the immunoglobulin G response to different COVID-19 vaccines in Brazil

Paula

Conzentino

Gonçalves

et al. 2022

Preprint

View full text Add to dashboard Cite

Vaccination is a strategy that confers protection against symptomatic infections and/or development of severe COVID-19. In Brazil, COVID-19 vaccination began in January 2021 and has been performed using vaccines from different manufactures including CoronaVac (Sinovac), ChAdOx1 (Oxford/AstraZeneca) and BNT162b2 (Pfizer/BioNTech). One of the main protective mechanisms triggered by vaccination involves the production of IgG antibodies reactive to the Spike antigen of SARS-CoV-2, the levels of which correlates with vaccine efficacy. Although phase III clinical studies confirmed the efficacy of the vaccines used in Brazil, there are just few studies comparing vaccine immunogenicity in a real-world scenario. This study aimed to depict the IgG response to natural infections and to vaccination using different types of vaccines at population scale in Matinhos, a city located in south of Brazil. Nucleocapsid seroconversion rates indicated that more than a quarter of the cohort has been subjected to natural infections by SARS-CoV-2 by the first trimester of 2022. Spike seroconversion rates achieved >95% by February 2022 and maintained stable as far as June 2022 confirming the effectiveness of the vaccination program. Immunogenicity concerning IgG reactive to Spike was higher using the BNT162b2 vaccine, followed by ChAdOx1 and CoronaVac. Natural infections boosted IgG levels reactive to Spike in those individuals that completed primary vaccination with ChAdOx1 and CoronaVac but not with BNT162b2. The levels of IgG reactive to Spike increased with the number of vaccine doses administered. The application of BNT162b2 as booster dose resulted in high levels of IgG reactive to Spike which were similar despite the type of the vaccine used during primary vaccination.

show abstract

Section: Discussionsupporting

confidence: 92%

“…This analysis revealed that both seroconversion rates and the levels of IgG reactive to Spike and S1 RBD were higher on those participants vaccinated with BNT16b2, followed by ChAdOx1 and CoronaVac, in agreement with other studies (Barin et al . 2022; Romero-Pinedo et al . 2022).…”

Section: Discussionmentioning

confidence: 99%

Populational analysis of the immunoglobulin G response to different COVID-19 vaccines in Brazil

Paula

Conzentino

Gonçalves

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…While mucosal immunization would induce SIgA antibodies, parenteral doses would improve systemic response [48][49][50]. Data from rodents showed that nasal immunization enhanced IgA in sera [46] and both sera and respiratory mucosa [47]. However, there is little evidence from human studies.…”

Section: Secretory Iga: the Mucosal Weaponmentioning

confidence: 99%

“…Current SARS‐CoV‐2 vaccines can also induce IgA, as it has been verified for the mRNA vaccines from Moderna (mRNA1273) and Pfizer/BioNTech (BNT162b2) and the viral vector vaccine from Oxford/Astrazeneca (ChAdOx1) [47].…”

Section: Immunological Defence On Mucosal Surfacesmentioning

confidence: 99%

“…However, there is little evidence from human studies. Vaccinated volunteers who had COVID‐19 previously, who are likely to have elicited IgA response, presented higher IgA titers [51] and more sustained IgA response [47] than subjects without COVID‐19 history. We could suggest that if the natural infection was considered as a nasal prime, the following parenteral vaccine would confer a better immune response.…”

Section: Immunological Defence On Mucosal Surfacesmentioning

confidence: 99%

See 1 more Smart Citation

Vaccines, adjuvants and key factors for mucosal immune response

Portilho

Gaspari

2022

Immunology

View full text Add to dashboard Cite

Vaccines are the most effective tool to control infectious diseases, which provoke significant morbidity and mortality rates. Most vaccines are administered through the parenteral route and can elicit a robust systemic humoral response, but they induce a weak T-cell-mediated immunity and are poor inducers of mucosal protection. Considering that most pathogens enter the body through mucosal surfaces, a vaccine that elicits protection in the first site of contact between the host and the pathogen is promising. However, despite the advantages of mucosal vaccines as good options to confer protection on the mucosal surface, only a few mucosal vaccines are currently approved. In this review, we discuss the impact of vaccine administration in different mucosal surfaces; how appropriate adjuvants enhance the induction of protective mucosal immunity and other factors that can influence the mucosal immune response to vaccines.

show abstract

Anti‐spike protein IgG antibody responses up to 3 months after the third dose of the BNT162b2 mRNA vaccine in medical care workers

Hirano

2024

J of Gen and Family Med

View full text Add to dashboard Cite

BackgroundThis study aimed to assess the changes in anti‐spike protein IgG antibody titer over time following mRNA vaccination (BNT162b2) against severe acute respiratory syndrome coronavirus 2.MethodsWe monitored IgG levels in 23 medical care workers (MCWs) for up to 3 months after administering the third dose of BNT162b2. Blood samples were periodically collected from all participants.ResultsFollowing the third dose, the median antibody titer increased to 252 and 327% compared with antibody levels at 1 and 3 months after the second dose, respectively. Additionally, compared with 1 month after the second dose, the median antibody titer decreased to 30.2 and 9.8% at 3 and 6 months, respectively, and to 39.1% at 3 months, compared with 1 month after the third dose.ConclusionAntibody levels declined quickly after the second dose but declined more slowly after the third dose, showing a booster effect. This study provides insights into the immunogenicity of booster doses and time intervals for booster vaccination strategies.

show abstract

Vaccine Type-, Age- and Past Infection-Dependence of the Humoral Response to SARS-CoV-2 Spike S Protein

Cited by 8 publications

References 39 publications

Populational analysis of the immunoglobulin G response to different COVID-19 vaccines in Brazil

Populational analysis of the immunoglobulin G response to different COVID-19 vaccines in Brazil

Vaccines, adjuvants and key factors for mucosal immune response

Anti‐spike protein IgG antibody responses up to 3 months after the third dose of the BNT162b2 mRNA vaccine in medical care workers

Contact Info

Product

Resources

About